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Abstract
Apolipoprotein E (apoE)-deficient mice develop marked hy-
perlipidemia as well as atherosclerosis and thus are an excel-
lent animal model for evaluating the potential for gene ther-
apy in human genetic dyslipoproteinemias. Recombinant
adenovirus containing either human apoE (rAdv.apoE) or
the reporter gene luciferase (rAdv.luc) were generated and
infused intravenously in apoE-deficient mice with preinfu-
sion plasma total cholesterol of 644±149 mg/dl and choles-
terol rich VLDL/IDL. After a single infusion of rAdv.apoE,
plasma concentrations of human apoE ranging from 1.5 to
650 mg/dl were achieved. Adenovirus-mediated apoE re-
placement resulted in normalization of the lipid and lipopro-
tein profile with markedly decreased total cholesterol
(103±18 mg/dl), VLDL, IDL, and LDL, as well as increased
HDL. Measurement of aortic atherosclerosis 1 mo after ade-
noviral infusion demonstrated a marked reduction in the
mean lesion area of mice infused with rAdv.apoE (58±8
X 103 ,um2) when compared with control mice infused with
rAdv.luc (161±19 X 103 ,um2; P < 0.0001). Thus, apoE
expression for 4 wk was sufficient to markedly reduce ath-
erosclerosis, demonstrating the feasibility of gene therapy
for correction of genetic hyperlipidemias resulting in athero-
sclerosis. The combined use of adenovirus vectors and the
apoE-deficient mouse represents a new in vivo approach
that will permit rapid screening of candidate genes for the
prevention of atherosclerosis. (J. Clin. Invest. 1995.
96:1612-1620.) Key words: apolipoprotein E * gene therapy
* atherogenesis - in vivo * adenoviridae
Introduction
Apolipoprotein E (apoE), a 36-kD plasma glycoapolipoprotein,
plays a key role in lipoprotein metabolism by facilitating the
cellular uptake of remnants of triglyceride-rich chylomicrons
and VLDL (for review see references 1 and 2). Human apoE
is polymorphic and consists of three major isoproteins of which
apoE-3 is the most common. In lipoprotein metabolism, apoE
Address correspondence to H. Bryan Brewer, Jr., National Institutes of
Health, Molecular Disease Branch, National Heart, Lung, and Blood
Institute, Building 10, Room 7Nl 15, 10 Center Drive MSC 1666,
Bethesda, MD 20892. Phone: 301-496-5095; FAX: 301402-0190.
Received for publication 29 March 1995 and accepted in revised
form 30 May 1995.
The Journal of Clinical Investigation, Inc.
Volume 96, September 1995, 1612-1620
serves as a ligand on lipoprotein particles for the LDL receptor
and has also been proposed as a ligand for LDL receptor-related
protein, the putative remnant receptor, as well as the VLDL
receptor (3-8). The important role that apoE plays in facilitat-
ing lipoprotein transport has been established in part by the
identification of patients with apoE deficiency (9-13) or, more
commonly, patients with a structural defect in apoE that results
in decreased affinity for the lipoprotein receptors (14-17). A
defect in the function of apoE leads to delayed plasma clearance
of remnants of triglyceride-rich lipoproteins and the develop-
ment of dysbetalipoproteinemia or type HI hyperlipoproteine-
mia. The majority of patients with type Ill hyperlipoproteinemia
have the apoE-2 isoform which has reduced binding to the
lipoprotein receptors. Type Ill hyperlipoproteinemia is charac-
terized by elevated plasma levels of cholesterol, triglycerides,
atherogenic cholesterol rich remnants of chylomicrons, and
VLDL, as well as by the presence of xanthomas and develop-
ment of premature cardiovascular disease.
A mouse model for apoE deficiency has been developed
using homologous recombination with apoE-targeted gene dis-
ruption in embryonic stem cells (18). The apoE-deficient mice
develop marked hypercholesterolemia with total cholesterol lev-
els five- to six-fold greater than control mice (19, 20). These
apoE-deficient mice have a dramatic shift in plasma lipoproteins
from HDL, the major lipoprotein in control mice, to cholesterol-
enriched remnants of chylomicrons and VLDL. Of particular
interest in the apoE-deficient mice is the development of sponta-
neous atherosclerosis on a normal chow diet (20-22). The
apoE-deficient mouse represents a unique model to study gene
replacement of a plasma apolipoprotein for correction of a ge-
netic dyslipoproteinemia. The correction of the apoE deficiency
in this animal model presents several interesting challenges.
For apoE to function in facilitating the clearance of lipoprotein
remnants, gene replacement must be followed by synthesis and
secretion of the apolipoprotein in a pathway that will permit it to
become associated with both hepatic proteoglycans and plasma
lipoproteins. In addition, to achieve replacement of apoE at
levels observed in normal control animals, it must be expressed
in the milligrams per deciliter level in plasma, that has not been
readily achieved in previous gene replacement studies. A recent
study indicates that bone marrow transplantation with replace-
ment of apoE by using apoE-expressing myeloid cells in apoE-
deficient mice may correct the metabolic defect as well the diet-
enhanced atherosclerosis in these animals (23). In humans and
normal mice, however, the major site of synthesis of apoE
appears to be the liver (2, 24).
In this report, we describe the successful correction of apoE
deficiency in apoE-deficient mice by using an alternative ap-
proach involving systemic delivery to mouse liver of recombi-
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Figure 1. Lipoprotein profiles. Lipoprotein analysis by FPLC of mouse plasma samples. (A) Control C57 black mouse, (B) apoE-deficient mouse,
(C) apoE-deficient mouse 4 d after rAdv.apoE infusion, (D) summary of cholesterol curves from A-C. Note the different vertical axes and the
superimposition of the cholesterol profile of the apoE-deficient mouse after rAdv.apoE injection and that of the control mouse (D). Relative elution
positions of different lipoproteins on FPLC are indicated in the panels.
nant adenovirus vectors expressing human apoE. Using this
approach, the marked hypercholesterolemia and abnormal lipo-
protein profile in apoE-deficient mice were normalized and
plasma apoE levels ranging from a normal level of 3-4 mg/dl
to 650 mg/dl were achieved. apoE expression for 4 wk resulted
in a significant reduction of aortic atherosclerotic mean lesion
area when compared with control apoE-deficient mice. These
combined results provide definitive evidence for the feasibility
of gene replacement as well as modulation of the atherosclerotic
process in the genetic dyslipoproteinemias resulting from apoli-
poprotein gene defects.
plasmid vector which contained cytomegalovirus (CMV)l enhancer and
promoter elements upstream and designated pCMVI2apoE. The 1.1-kb
apoE gene was sequenced using the Sanger dideoxynucleotide method
(27) and the proper orientation was confirmed.
Human embryonic kidney 293 cells (28) of low passage number
were used for cell culture studies (American Type Culture Collection,
Rockville, MD). The plasmid construct pCMV12apoE was transfected
using calcium phosphate (29) to determine functionality, and apoE was
identified in the culture media by an apoE ELISA and immunoblotting
with an apoE monospecific antibody. The apoE gene was subcloned into
a shuttle vector (pAdl2apoE) containing CMV enhancer and promoter
elements, an SV40 polyadenylation signal, and the El region of the
human adenovirus (AdS) (30). Recombinant El-deleted adenovirus
Methods
Generation of recombinant adenovirus. A full-length human apoE
cDNA (apoE3 isoform) (25, 26) was cloned into a pUC18-derived
1. Abbreviations used in this paper: CMV, cytomegalovirus; FPLC, fast
protein liquid chromatography.
Table L Plasma Lipids and Lipoproteins in apoE-deficient and Normal Mice
TC TG PL CE FC HDL-C
mg/dl
ApoE-deficient (n = 15) 644±149* 111±74 341±82* 420±121* 223±49* 23±6* (n = 7)
Controls (n = 15) 103±13 76±17 185±17 77±10 26±4 69±3 (n = 7)
The mean±SD of all lipid values are shown. TC, total cholesterol; TG, triglycerides; PL, phospholipids; CE, cholesterol ester; FC, free cholesterol.
* P < 0.001.
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Figure 2. Relative tissue distribution of luciferase activity. Organs were
harvested from C57 black mice (n = 3) 4 d after rAdv.luc injection
and the assay performed on 100-mg samples of homogenized tissues as
described in Methods. Luciferase activity is expressed as a percentage
of total activity present in organs analyzed.
was generated after cotransfection of pAdl2apoE and pJM17 (AdS
genome) in 293 cells as described previously (31). The recombinant
virus was propagated in 293 cells and purified by cesium chloride density
ultracentrifugation. The purified virus designated rAdv.apoE was titered
and diluted in 0.2% mouse albumin (Sigma Chemical Co., St. Louis,
MO) before infusion into the animals. The same methodology was
performed to generate the recombinant adenovirus containing the lucif-
erase gene (32), designated rAdv.luc.
apoE-deficient mice. apoE-deficient mice, obtained from University
of North Carolina, were bred and housed at the National Institutes of
Health (NIH) under protocols approved by the Animal Care and Use
Committee of the National Heart, Lung, and Blood Institute. Animals
had free access to food (NIH 07 chow diet, 4.5% fat, 0% cholesterol;
Zeigler Brothers Co., Gardners, PA) and water. All animal procedures
were performed according to NIH guidelines (33). Age- and weight-
matched mice (- 4 mo and 25 grams, respectively) of both sexes re-















C57black (n = 4) 7.0±1.6
apoE quantitation was determined by ELISA and plasma samples were
assayed 4 d after either 2 x 108 or 3 x 109 pfu rAdv.apoE injection in













Figure 3. apoE immunoblot of mouse plasma and FPLC lipoprotein
fractions. Analysis of apoE plasma expression before (day 0) and after
(days 4, 8, 20, and 34) rAdv.apoE infusion revealed the presence of an
intact 36-kD apoE band. Analyses of the individual fractions across the
FPLC elution profile demonstrated apoE associated primarily with
mouse HDL in control (C) as well as low (E def Low Exp.) and high
expressing (E def High exp.) apoE-deficient animals after rAdv.apoE
infusion. Standard (Std.) is purified human apoE (10 ng).
ceived intravenous injections of adenovirus through the saphenous vein.
All plasma samples were drawn at 11 a.m. after a 4-h fast.
Luciferase assay. Animals were killed 4 d after rAdv.luc virus infu-
sion, and the individual organ tissues were frozen. The thawed samples
were homogenized using a hand-held homogenizer (Omni International,
Marietta, GA), subjected to three freeze/thaw cycles, and centrifuged.
The supernatants were assayed on a luminometer (Monolight 2010;
Analytic Luminescence Laboratory, San Diego, CA) using luciferin
substrate (34).
Plasma lipid, lipoprotein, and apolipoprotein analyses. Total cho-
lesterol, triglycerides, phospholipids, and free cholesterol were assayed
using enzymic kits from Sigma Diagnostics (St. Louis, MO) and Wako
Chemicals USA, Inc. (Richmond, VA). Assays were performed on 10-
pl aliquots of fasting plasma samples using the COBAS MIRA Plus
automated chemistry analyzer (Roche Diagnostic Systems, Inc., Branch-
burg, NJ). Cholesterol ester values were calculated as the difference
between total cholesterol and free cholesterol concentrations (35).
HDL-cholesterol was measured via dextran sulfate (Ciba-Corning, Ob-
erlin, OH) precipitation. Plasma lipoproteins were analyzed by fast pro-
tein liquid chromatography (FPLC) using two Superose 6 columns in
series (36) (Pharmacia LKB Biotechnology, Inc., Piscataway, NJ). 50-
,ul plasma samples from control and apoE-deficient mice before and
after adenoviral infusion were analyzed individually. Lipoproteins were
eluted at a constant flow rate of 0.3 ml/min with PBS buffer containing
1 mM EDTA and 0.02% sodium azide. FPLC profiles of individual
mice are shown and are representative of 12 analyses obtained during
the course of the study (Fig. 1).
Human apoE in mouse plasma was quantitated by a sandwich ELISA
using microtiter immunoassay plates (Immulon 1; Dynatech Labora-
tories, Chantilly, VA) coated with a monoclonal apoE antibody ABE2
(University of Ottawa Heart Institute, Ottawa, Ontario, Canada) for
capture. Purified mouse apoE and recombinant human apoE3 were quan-
titated by amino acid analysis. Purified recombinant human apoE3 in
progressive dilutions in apoE-deficient human plasma was used to gener-
ate a standard curve from 0 to 200 ng/ml. A polyclonal rabbit apoE
antibody followed by a goat anti-rabbit peroxidase-conjugated antibody
was used for detection. The within-run coefficient of variation of the
apoE assays was 12%. Mouse apoE quantitation was performed by
computerized densitometry of apoE immunoreactive bands on protein
immunoblots as described below. Purified mouse apoE was used to
generate a standard curve on each gel from 5 to 40 ng and a polyclonal
apoE antibody (Biodesign International, Kennebunkport, ME) was used
for detection.
Immunoblotting was performed on a 10% Tris glycine gel (Novex,
San Diego, CA) using standard Laemmli buffer containing SDS and
mercaptoethanol. The samples (1 pIl of plasma diluted 10-fold with
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Table III. Plasma Lipids and Lipoproteins after Adenoviral Injection
TC TG PL CE FC HDL-C
mg/dl
rAdv.luc (n = 8) 739±165 130±44 428±129 492±105 247±90 21±6
rAdv.apoE (n = 7) 103±18* 97±32 194±34* 52±10* 52±12* 85±44t
Controls (n = 15) 103±13 76±17 185±17 77±10 26±4 69±3
Plasma samples were assayed 4 d after either rAdv.luc or rAdv.apoE injection in apoE-deficient mice. Comparison of these two groups was used
for statistical analysis. Controls represent values in noninjected C57 black mice. * P < 0.001; t P < 0.002.
PBS) were electophoresed for 1.5 h and transferred to an Immobilon
polyvinylidene difluoride membrane (Millipore Corp., Bedford, MA)
for 2 h. Blocking was performed with 3% BSA followed by incubation
with a human apoE specific monoclonal antibody (ABE 1, University
of Ottawa Heart Institute) for 12 h. Secondary antibody and detection
were performed with a silver enhancement of a gold-labeled anti-mouse
antibody using a 2-h incubation (Auroprobe; Amersham International,
Buckinghamshire, United Kingdom).
Evaluation of atherosclerosis. The heart and attached section of
ascending aorta were dissected en bloc and placed in 0.9% saline for 1
h followed by fixing in 4% formaldehyde for 24 h and then 10% formal-
dehyde for 5 d as described previously (37). The specimens were em-
bedded in 25% gelatin and then sectioned using a cryostat at -250C.
The aortic root and ascending aorta were sectioned at a thickness of 10
,um and alternate sections were saved on slides and stained with Oil-
red-O for neutral lipids and hematoxylin for nucleic tissue. Five sections
per animal were evaluated for the cross-sectional area of lesions from
the aortic root for a distance of - 350 jim at 80 ,m intervals (37, 38).
The groups were statistically analyzed using unpaired Student's t test.
Results
The plasma lipids and lipoproteins present in the apoE-deficient
and control C57black mice are summarized in Table I. When
compared with control mice, the apoE-deficient mice were
markedly hyperlipidemic with plasma total cholesterol, choles-










greater than control mice and plasma triglycerides and phospho-
lipids twofold greater. Furthermore, HDL is reduced to one-
third of the normal levels. The lipoprotein profiles determined
by FPLC for the control and apoE-deficient mice are shown in
Fig. 1, A and B. In control mice (Fig. 1 A), the lipoprotein
profile revealed HDL as the predominant lipoprotein with only
small amounts of VLDL and LDL. In contrast, the major lipo-
proteins in the apoE-deficient mice (Fig. 1 B) were VLDL and
IDL with a significant reduction in HDL. The combined lipids
and lipoprotein profiles in the apoE-deficient mice are consistent
with delayed clearance of triglyceride-rich lipoproteins leading
to markedly elevated cholesterol-enriched remnant lipoproteins.
To determine the efficacy of apoE gene replacement, apoE-
deficient mice were infused intravenously with a recombinant
adenovirus containing the apoE gene designated rAdv.apoE
driven by a CMV promoter and enhancer. A similar recombi-
nant adenovirus containing the luciferase gene (rAdv.luc) was
used as a control for viral-induced changes in plasma lipopro-
teins. The recombinant luciferase adenovirus construct was also
used for the determination of the tissue distribution of the adeno-
viral-mediated gene delivery because of the availability of a
sensitive quantitative assay (39). The tissue distribution of
transgene expression after intravenous rAdv.luc infusion is sum-
marized in Fig. 2. Consistent with previous reports (40-42)
which have demonstrated expression of the transgene in virtu-
ally all the hepatocytes examined, the liver was the major organ
Figure 4. Plasma cholesterol values after adeno-
viral infusion. Cholesterol values in apoE-defi-
cient mice after either rAdv.luc (closed circles,
n = 8) or rAdv.apoE (closed squares, n = 7)
infusion. Values are mean±SD.
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Figure 5. Aortic atherosclerosis after adenoviral infusion. 10 apoE-
deficient mice on a normal chow diet (3.4% fat, 0% cholesterol) were
used for determination of total lesion area in the ascending aorta. Aortic
sections from apoE-deficient mice at 5 mo of age served as controls (n
= 15 sections). 4-mo-old apoE-deficient mice were infused with either
rAdv.luc or rAdv.apoE and killed 1 mo later at the age of 5 mo. Aortic
sections harvested from mice infused with rAdv.apoE (n = 20 sections)
had markedly lower aortic atherosclerosis when compared with apoE-
deficient mice after infusion with rAdv.luc (n = 15 sections, P
< 0.0001). Error bars indicate SEM.
of luciferase transgene expression. Low level expression of the
luciferase transgene was also detected in the spleen, lung, and
heart.
Infusion of apoE-deficient mice with either 2 x 108 or 3
x 109 pfu of rAdv.apoE resulted in low and high levels of
expression of plasma apoE, respectively. At 4 d after injection,
the plasma apoE levels ranged in the low expressors from 1.5
to 35 mg/dl (mean = 11.3 mg/dl, n = 7) to 536-648 mg/dl
in the high expressor animals (Table II). Further evidence of
apoE production was obtained by immunoblot analysis of
mouse plasma (Fig. 3). Analysis of plasma from the apoE-
deficient mice starting at day 4 after injection with rAdv.apoE
revealed the 36-kD E apolipoprotein band which could be de-
tected in decreasing intensity for up to 34 d. Marked overex-
pression of apoE in the high expressor animal group was tran-
sient, with levels of apoE decreasing to the range of the low
expressor group by 8-12 d.
The plasma lipids and lipoproteins of the apoE-deficient
mice injected with rAdv.apoE as compared with apoE-deficient
animals injected with rAdv.luc and control mice are summarized
in Table III. 4 d after injection of rAdv.apoE, the markedly
hypercholesterolemic lipoprotein profile of the apoE-deficient
mice was dramatically altered and was comparable with the
lipoprotein profile in control mice. The total cholesterol values
in rAdv.apoE-treated mice ranged from 80 to 137 mg/dl on
day 4. Thus, a similar normalization of the lipoprotein profile
was achieved in animals with apoE expression ranging from
1.5 to 35.0 mg/dl, indicating that only 1-2 mg/dl of functional
E apolipoprotein or 20% of normal plasma apoE levels was
sufficient to achieve a physiological correction of the lipid ab-
normalities. No significant change in the lipoprotein profile was
observed when the apoE-deficient mice were injected with rAd-
v.luc, indicating that injection of an adenovirus with an irrele-
vant transgene had no effect on the plasma lipids and lipopro-
teins in the apoE-deficient mice.
The FPLC profiles of the plasma lipoproteins of the apoE-
deficient mice at day 4 after rAdv.apoE infusions are shown in
Fig. 1, C and D. The marked elevation of the cholesterol-rich
VLDL and IDL in the apoE-deficient mice after rAdv.apoE
injection was normalized to a profile that was similar to control
mice with HDL as the major plasma lipoprotein. Immunoblot
analysis of the individual fractions across the FPLC elution
profile revealed the presence of apoE primarily in the apoA-I
containing HDL FPLC fractions, indicating that apoE had been
incorporated into the mouse plasma lipoproteins (Fig. 3, right
lanes).
The duration of changes in the plasma lipids after rAdv.apoE
infusion is illustrated in Fig. 4. The apoE-deficient mice receiv-
ing rAdv.apoE had a rapid decrease in total cholesterol by day
2 with a maximum correction at day 4 and then a gradual return
toward baseline. By day 30, the plasma cholesterol levels were
still approximately half those of the untreated apoE-deficient
mice. A reduction in plasma cholesterol persisted in the rAd-
v.apoE-injected mice for up to 60 d, thus establishing the ability
of the transgene to synthesize and secrete apoE in sufficient
levels to modulate lipoprotein metabolism. The animals with
transient marked overexpression of apoE had similar cholesterol
reduction (total cholesterol = 161 mg/dl on day 8) and expres-
sion as the low expressor group with plasma cholesterol re-
turning toward baseline by day 46.
To determine the effect of apoE gene replacement on spon-
taneous atherosclerosis, apoE-deficient mice were killed, and
aortic atherosclerotic lesion areas were examined and quanti-
tated histologically. Previous analyses of atherosclerotic lesion
development in apoE-deficient mice in our laboratory demon-
strated initial aortic lesions forming at 3 mo of age with rapid
progression to complex atherosclerotic lesions by 5 mo of age
(data not shown) consistent with animals analyzed in previously
reported studies (20, 21). Therefore, 4-mo-old male animals
with aortic atherosclerotic lesion area of - 30 X 103 um2 were
chosen for the study and remained on a normal chow diet (4.5%
fat, 0% cholesterol) during the study. apoE-deficient mice had
a mean lesion area per section of 136±18 X 103 ILm2 (±SEM;
n = 15 sections from three animals) at 5 mo of age (Fig. 5). As
previously described (20, 21), these animals had characteristic
atherosclerotic lesions that started in the aortic sinus and ex-
Figure 6. Proximal aortic sections from apoE-deficient mice. All sections were stained with Oil-red-O and hematoxylin and then counterstained
with light green. Sections from an apoE-deficient mouse at 5 mo of age are on the left; sections from an apoE-deficient mouse at 5 mo of age after
receiving rAdv.apoE 1 mo before on the right. The apoE-deficient animal has significant atherosclerotic changes with marked lipid accumulation
and fibrosis (A and B). An animal of the same age after rAdv.apoE treatment has an absence of complex lesion development with minimal lipid
staining of the intima (C and D). A and C, x30; B and D, x75.
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tended distally along the ascending aorta in all sections exam-
ined. The raised lesions had marked red staining areas using
Oil-red-O indicating lipid accumulation with lipid-laden macro-
phages, extracellular lipid deposits, necrosis, and fibrosis (Fig.
6, A and B). Another subset of 4-mo-old apoE-deficient mice
was infused with either rAdv.luc or rAdv.apoE and then killed
4 wk later at 5 mo of age. The rAdv.luc-infused mice had a
mean lesion area per section of 161±19 X 103 ,im2 (n = 15
sections from three animals) and had lesions similar to control
apoE-deficient mice. However, apoE-deficient animals express-
ing apoE had mean aortic lesion areas that were significantly
smaller (58±8 x 103 1um2; n = 20 sections from four animals;
P < 0.0001) than the animals infused with rAdv.luc (Fig. 5).
The aortas from the apoE-treated mice showed minimal lipid
staining and an absence of complex lesion formation (Fig. 6,
C and D) similar to younger animals.
Discussion
During the last two decades, there have been major advances
in our understanding of the molecular defects that result in
the genetic dyslipoproteinemias. In addition, several different
dyslipoproteinemic animal model systems have been developed
in mice by gene deletion using homologous recombination. Ge-
netic defects in the plasma apolipoproteins are a frequent cause
of the human genetic dyslipoproteinemias. The plasma apolipo-
proteins function in lipoprotein metabolism as cofactors for
enzymes, structural proteins for lipoprotein biosynthesis, and
ligands for interactions with lipoprotein receptors. Structural
defects in apolipoprotein genes result in clinical phenotypes
with characteristic changes in the plasma lipoproteins. The ge-
netic dyslipoproteinemias are ideal candidates for gene therapy
since the molecular defects in the genes have been established
definitively and many of the diseases have significant sequelae
to warrant treatment including premature cardiovascular and
peripheral vascular disease or recurrent pancreatitis and pancre-
atic insufficiency (1).
In this study, we have selected the apoE-deficient mouse to
determine the feasibility of apolipoprotein gene replacement in
the genetic dyslipoproteinemias. To achieve an effective correc-
tion of the gene defect in the apoE-deficient animals, the apoE
transgene must be expressed, apoE must be secreted from the
liver, and the protein must associate with hepatic proteoglycans
as well as plasma lipoproteins. The role of apoE in lipoprotein
remnant clearance is to serve as a ligand on hepatic proteogly-
cans for the initial interaction of the lipoprotein particle with
the cell after which there is an apoE-mediated specific interac-
tion with the membrane lipoprotein receptors (3-8). As re-
viewed above, the apoE transgene must be expressed in the
milligrams per deciliter range to achieve plasma levels similar
to those present in humans and normal mice. Previous studies
have demonstrated that intravenous delivery of recombinant
adenovirus results in the expression of apoA-I (42) and Factor
IX (40) in normal mice as well as successful correction of the
metabolic defects associated with ornithine transcarbamylase
(43) and LDL-receptor deficiency (41) in two mouse models
for these genetic disorders. However, milligrams/deciliter lev-
els of transgene expression associated with complete correction
of a genetic disease have not been consistently achieved in most
in vivo adenoviral gene therapy studies in mice (40-44). One
of the major limitations of the currently used adenovirus vector
system is the short-term expression of the transgene (40, 41,
45-48) which in most cases is limited to less than 2 mo. Recent
data suggest that this limited expression is due at least in part
to the development of an immune response directed against
viral late gene proteins that continue to be expressed with the
current generation of adenovirus vectors (43, 49). Interestingly,
despite the ability of the adenovirus vectors to transduce a wide
variety of cells (28, 43, 50-55), intravenous infusion appears
to preferentially target the liver, the major site of synthesis of
plasma lipoproteins and apoE (40, 42, 43). Thus, we used
recombinant adenovirus to evaluate the feasibility of correcting
the marked hyperlipidemia and atherosclerosis in apoE-deficient
mice after transient delivery of the human apoE gene to the
liver.
Using the replication-deficient adenovirus vector system, we
have achieved complete correction of the hypercholesterolemic
lipoprotein profile in the apoE-deficient mouse. Plasma choles-
terol levels were reduced from the 650 mg/dl range to the 100-
150 mg/dl levels of control mice. apoE could be detected in
plasma by immunoblot analysis and by ELISA, and both low
as well as high plasma levels of apoE associated primarily with
mouse HDL were achieved. Interestingly, near the completion
of our studies, Stevenson et al. reported (56) the lipoprotein
profile observed after adenovirus-mediated gene transfer in
apoE-deficient mice and indicated that the majority of expressed
apoE associated with VLDL. However, in their study, an adeno-
viral construct with a Rous sarcoma virus (RSV) promoter was
used resulting in apoE expression in the range of 0.12 mg/
dl. This level of apoE expression did not result in complete
normalization of the elevated plasma VLDL when analyzed by
FPLC, and the expressed apoE was associated with the choles-
terol-rich VLDL. In contrast, in our report, FPLC analysis of the
plasma lipoproteins of the apoE-deficient mice after rAdv.apoE
infusion revealed a virtual complete shift from the cholesterol-
rich VLDL and IDL to HDL, the predominant lipoprotein char-
acteristic of normal mice. The expressed apoE was associated
primarily with HDL in our studies. Expression of the transgene
was detected up to 1 mo after adenoviral injection and was
accompanied by persistent cholesterol reduction.
Since most strains of mice are resistant to atherosclerosis,
atherogenic diets to induce the development of atherosclerotic
lesions have been needed in previous studies (38, 57). How-
ever, in the apoE-deficient animal, lesions form even when the
animals are fed a normal chow diet. The effect of correction of
the apoE gene defect on the development of this spontaneous
atherosclerosis in the apoE-deficient mouse was determined in
apoE-deficient mice 4 wk after rAdv.apoE infusion. The expres-
sion of apoE and correction of the hyperlipidemia for up to
4 wk after apoE gene replacement were sufficient enough to
significantly reduce atherosclerosis in apoE-deficient mice.
These animals demonstrated a significant decrease in the mean
lesion area in the aortas when compared with control apoE-
deficient mice infused with rAdv.luc or left untreated. Compari-
son of lesion area in 4-mo-old apoE-deficient mice and the
rAdv.apoE-treated apoE-deficient animals suggests that the sig-
nificant reduction in atherosclerosis in the latter group primarily
reflects the prevention of progressive lesion formation rather
than regression. This is consistent with the observation that,
compared with the control groups, the rAdv.apoE-infused apoE-
deficient animals had lesions with minimal lipid staining of the
intima and no evidence of prior fibrosis. Presently, no practical
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noninvasive method exists to assess the baseline atherosclerosis
before adenoviral infusion in each individual animal to defini-
tively document regression of atherosclerotic lesions. However,
older animals with more advanced lesions may be useful in
subsequent studies to assess regression of atherosclerosis with
transient apoE expression. Of major importance, however, is the
finding that adenovirus-mediated transient expression of apoE
resulted in modification of a major, complex clinical end point,
atherosclerosis, in adult apoE-deficient mice.
These combined results provide definitive evidence that
marked hyperlipidemia and atherosclerosis resulting from a mo-
lecular defect in a plasma apolipoprotein can be effectively
corrected by adenovirus-mediated gene therapy. Based on these
studies, we propose that the combined use of adenovirus vectors
and the apoE-deficient mouse may provide a new and novel
approach for the rapid screening of candidate genes for preven-
tion of atherosclerosis.
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